Clinical outcomes: antileukemic responses and survival
| . | VEN cohort (n = 37), n (%) . | TPC cohort (n = 90), n (%) . | P value . |
|---|---|---|---|
| Best response∗ | Missing n = 6 | ||
| CR | 12 (32) | 27 (32) | 1.0 |
| CRi | 11 (30) | 8 (10) | .012 |
| MLFS | 5 (13) | 0 (0) | .002 |
| w/o blast clearance (PR/PD) | 8 (22) | 39 (46) | .015 |
| Dead | 1 (3) | 10 (12) | .170 |
| Overall response | Missing n = 6 | ||
| ORR (CR/CRi) | 23 (62) | 35 (42) | .049 |
| ORR (CR/CRi)† | 20 (59) | 35 (42) | .106 |
| ORR (CR/CRi)‡ | 20 (59) | 20 (29) | .005 |
| Early mortality | |||
| 30-d mortality | 1 (3) | 7 (8) | .436 |
| 60-d mortality | 2 (5) | 15 (17) | .149 |
| Median follow-up (95% CI), mo | 34.3 (28.3-45.3) | 21.0 (18.0-54.4) | .300 |
| Bridging to allo-HCT | .409 | ||
| Transplant | 27 (73) | 57 (63) | |
| No transplant | 10 (27) | 33 (37) | |
| Remission status before allo-HCT, excluding 16 patients with direct allo-HCT (n = 65 [of 68]) | Missing n = 3 | .095 | |
| CR/CRi/MLFS/PR | 23 (85) | 25 (66) | |
| SD/PD | 4 (15) | 13 (34) | |
| Survival | |||
| Median OS for all patients from the start of salvage treatment (95% CI), mo | 15.8 (10.6 to NE) | 10.5 (6.8-19.6) | .15 |
| Median OS censored at allo-HCT (95% CI), mo | 6.7 (6.2 to NE) | 5.0 (4.6-16.6) | .70 |
| . | VEN cohort (n = 37), n (%) . | TPC cohort (n = 90), n (%) . | P value . |
|---|---|---|---|
| Best response∗ | Missing n = 6 | ||
| CR | 12 (32) | 27 (32) | 1.0 |
| CRi | 11 (30) | 8 (10) | .012 |
| MLFS | 5 (13) | 0 (0) | .002 |
| w/o blast clearance (PR/PD) | 8 (22) | 39 (46) | .015 |
| Dead | 1 (3) | 10 (12) | .170 |
| Overall response | Missing n = 6 | ||
| ORR (CR/CRi) | 23 (62) | 35 (42) | .049 |
| ORR (CR/CRi)† | 20 (59) | 35 (42) | .106 |
| ORR (CR/CRi)‡ | 20 (59) | 20 (29) | .005 |
| Early mortality | |||
| 30-d mortality | 1 (3) | 7 (8) | .436 |
| 60-d mortality | 2 (5) | 15 (17) | .149 |
| Median follow-up (95% CI), mo | 34.3 (28.3-45.3) | 21.0 (18.0-54.4) | .300 |
| Bridging to allo-HCT | .409 | ||
| Transplant | 27 (73) | 57 (63) | |
| No transplant | 10 (27) | 33 (37) | |
| Remission status before allo-HCT, excluding 16 patients with direct allo-HCT (n = 65 [of 68]) | Missing n = 3 | .095 | |
| CR/CRi/MLFS/PR | 23 (85) | 25 (66) | |
| SD/PD | 4 (15) | 13 (34) | |
| Survival | |||
| Median OS for all patients from the start of salvage treatment (95% CI), mo | 15.8 (10.6 to NE) | 10.5 (6.8-19.6) | .15 |
| Median OS censored at allo-HCT (95% CI), mo | 6.7 (6.2 to NE) | 5.0 (4.6-16.6) | .70 |
PD, progressive disease; PR, partial remission; SD, stable disease; w/o, without.
P values < 0.05 are displayed in bold.
Best response in VEN-treated patients after up to 3 treatment cycles and best response in TPC patients after first salvage therapy.
ORR (CR/CRi) excluding patients with molecular relapse/persistence.
ORR (CR/CRi) excluding patients with molecular relapse/persistence or direct allo-HCT.